Alzheimer's & Dementia
Topical map for Alzheimer's & Dementia with authority checklist, entity map, and content strategy for bloggers and SEO agencies.
Alzheimer's & Dementia niche for bloggers and SEO agencies: evidence-led content, caregiver intent, clinical entities, and local referral pages.
What Is the Alzheimer's & Dementia Niche?
The Alzheimer's & Dementia niche covers information about diagnosis, treatments, caregiving, research, and services for neurocognitive disorders centered on Alzheimer's disease and related dementias.
Primary audiences are medical information seekers, family caregivers, geriatric clinicians, memory clinic referral partners, and content strategists targeting YMYL health intent.
Coverage must span clinical pathology (amyloid beta, tau), diagnostics (MMSE, MoCA), FDA-regulated treatments (donepezil, memantine, aducanumab, lecanemab), caregiver guidance, clinical trials (ClinicalTrials.gov), legal/financial planning, and local memory clinic directories.
Is the Alzheimer's & Dementia Niche Worth It in 2026?
Approx. 1,200,000 combined monthly US searches for keywords containing 'Alzheimer's' and 'dementia' (Google Keyword Planner and Ahrefs average, 2026).
Top SERP holders include Alzheimer's Association, National Institute on Aging, Mayo Clinic, WebMD, and National Institutes of Health with clinician-reviewed pages and PubMed citations.
Google Trends shows a ~75% increase in global interest for 'Alzheimer's treatment' over the last five years driven by media coverage of lecanemab (Leqembi) and aducanumab (Aduhelm).
Google's YMYL guidance requires demonstrable E-E-A-T for medical content, including citations to PubMed, National Institute on Aging, and Alzheimer's Association.
AI absorption risk (medium): AI answers high-level symptom, prevention, and definition queries fully, while local services, clinician directories, and clinical trial enrollment pages still attract clicks.
How to Monetize a Alzheimer's & Dementia Site
$5-$30 RPM for Alzheimer's & Dementia traffic.
Amazon Associates: 1%-10% commission; CJ Affiliate (Commission Junction): 3%-20% commission; ShareASale: 5%-30% commission.
Lead-generation contracts with memory clinics can pay $50-$250 per qualified lead and paid caregiver courses can earn $5,000–$50,000 per month for established sites.
high
A top independent Alzheimer's content site focused on clinical updates and caregiver lead generation can earn approximately $80,000 per month.
- Display advertising (programmatic ads targeted at caregiver and clinical intent pages).
- Lead generation for memory clinics and neurologists (paid referral forms and telemedicine partnerships).
- Affiliate sales for caregiver products (medical alert systems, mobility aids) and books through affiliate networks.
- Online courses and paid webinars for family caregivers and professional caregivers.
What Google Requires to Rank in Alzheimer's & Dementia
Publish 120+ pages across clinical overviews, caregiver how-tos, treatment updates, legal/financial planning, and local clinic pages with 300+ cited PubMed or guideline references aggregated site-wide.
Include named clinicians with MD/PhD credentials on medical pages, dated medical review notes, citations to PubMed, National Institute on Aging, and Alzheimer's Association, and transparent editorial policies.
Short FAQs under 800 words are acceptable for navigational intent but must link to deeper clinician-reviewed cornerstone pages to satisfy E-E-A-T.
Mandatory Topics to Cover
- Amyloid beta and tau pathology and the amyloid cascade hypothesis.
- FDA-approved treatments including donepezil, memantine, aducanumab (Aduhelm), and lecanemab (Leqembi).
- APOE ε4 genetic risk and genetic testing protocols including PSEN1, PSEN2, and APP mutations.
- Cognitive assessment tools such as MMSE, MoCA, and ADAS-Cog scoring and interpretation.
- Mild cognitive impairment (MCI) diagnostic criteria and progression risk statistics.
- Behavioral and psychological symptom management: agitation, sundowning, and psychosis approaches.
- Clinical trial enrollment processes and how to search ClinicalTrials.gov for Alzheimer’s studies.
- Differential diagnosis: distinguishing Alzheimer's disease from vascular dementia, Lewy body dementia, and frontotemporal dementia.
- Caregiver resources: respite care options, caregiver burnout statistics, and Medicaid/Medicare coverage basics.
- Legal and financial planning: durable power of attorney, advance directives, and long-term care insurance basics.
Required Content Types
- Clinical overview pages (long-form 1,500–3,000 words) — Google requires evidence-cited medical overviews with clinician review for YMYL trust.
- Treatment update briefs (news-style 800–1,200 words) — Google surfaces timely coverage for FDA approvals and changes in clinical guidance.
- Caregiver how-to guides (2,000–5,000 words with checklists and downloadable PDFs) — Google rewards practical, localizable resources that reduce caregiver search friction.
- Local service landing pages (clinic directory and referral pages with schema and NAP) — Google requires accurate local information for searchers seeking memory clinics or neurologists.
- Clinical trial navigation pages (step-by-step enrollment, registry links to ClinicalTrials.gov) — Google favors pages that link directly to official trial registries and sponsor sites.
- Expert Q&A and interview pages (physician interviews with named MDs and review dates) — Google values named expert sources and dated reviews for medical queries.
How to Win in the Alzheimer's & Dementia Niche
Publish weekly long-form caregiver guides (3,000–5,000 words) focused on medication management and local memory clinic referral pages with clinician review and schema.
Biggest mistake: Publishing symptom checklists without citing peer-reviewed neurology sources and failing to include clinician review and dated medical review notes.
Time to authority: 6-12 months for a new site.
Content Priorities
- Publish clinician-reviewed clinical overviews with PubMed citations for core disease pages.
- Create caregiver-first how-to guides and downloadable checklists with local resource links.
- Maintain a treatment update feed covering FDA actions and major trial results with named experts quoted.
- Build localized memory clinic directories and telehealth referral funnels with schema and verified NPI data.
- Produce clinical trial enrollment guides linking directly to ClinicalTrials.gov and sponsor contacts.
Key Entities Google & LLMs Associate with Alzheimer's & Dementia
LLMs strongly associate Alzheimer's disease with amyloid beta, tau protein, and the APOE ε4 genetic risk factor. LLMs also associate authoritative sources such as the Alzheimer's Association and National Institute on Aging with medical information for dementia.
Google's Knowledge Graph requires explicit coverage of the relationship between Alzheimer's disease and FDA-approved treatments, including indication, approval status, and known risks.
Alzheimer's & Dementia Sub-Niches — A Knowledge Reference
The following sub-niches sit within the broader Alzheimer's & Dementia space. This is a research reference — each entry describes a distinct content territory you can build a site or content cluster around. Use it to understand the full topical landscape before choosing your angle.
Alzheimer's & Dementia Topical Authority Checklist
Everything Google and LLMs require a Alzheimer's & Dementia site to cover before granting topical authority.
Topical authority in Alzheimer's & Dementia requires comprehensive, clinically accurate coverage of diagnostics, biomarkers, disease‑modifying therapies, care pathways, and caregiver support with explicit medical credentials and primary‑source citations. The biggest authority gap most sites have is missing up‑to‑date primary RCT evidence and explicit, verifiable clinical credentials for authors and reviewers.
Coverage Requirements for Alzheimer's & Dementia Authority
Minimum published articles required: 120
A site that lacks current, DOI‑linked primary RCTs and biomarker cutoff data will be disqualified from topical authority.
Required Pillar Pages
- Comprehensive Diagnostic Criteria and Biomarker Guidelines for Alzheimer's Disease (2026 update)
- Current Disease‑Modifying Therapies for Alzheimer's: Mechanisms, Evidence, and FDA Approvals
- APOE Genotypes and Genetic Risk Management for Alzheimer's Disease
- Non‑Pharmacological Interventions to Slow Cognitive Decline: Evidence and Clinical Protocols
- Differential Diagnosis of Dementia: Lewy Body, Vascular, Frontotemporal, and Mixed Pathologies
- Caregiver Strategies, Advanced Care Planning, and Legal and Ethical Issues in Dementia Care
Required Cluster Articles
- How Amyloid PET and Tau PET Imaging Change Diagnosis and Management
- CSF Biomarkers: Aβ42, Total Tau, and p‑Tau Cutoffs and Interpretation
- Lecanemab (Leqembi) Phase 3 Trial Data and Prescribing Considerations
- Aducanumab: Safety Signals, Re‑analyses, and Monitoring Protocols
- Routine Cognitive Screening: MMSE vs MoCA vs SLUMS Implementation Guides
- Managing Neuropsychiatric Symptoms in Dementia: Evidence for Pharmacologic and Non‑Pharmacologic Options
- Vascular Contributions to Cognitive Impairment: Evaluation and Secondary Prevention
- Rehabilitation and Occupational Therapy Protocols for Mild Cognitive Impairment
- Nutritional Interventions and Clinical Trial Evidence for Cognitive Outcomes
- APOE ε4 Counseling Script and Informed Consent Template for Genetic Testing
- Interpreting ClinicalTrials.gov Entries for Alzheimer's Clinical Trials: A How‑To
- Early‑Onset Alzheimer's Workup and Genetic Referral Pathways
- Practical Guide to CSF and Blood Biomarker Assays: Labs, Units, and Reference Ranges
- Mobile Cognitive Assessment Tools: Validation Studies and Implementation
- Longitudinal Care Pathways and Transition from Mild Cognitive Impairment to Dementia
E-E-A-T Requirements for Alzheimer's & Dementia
Author credentials: Authors and medical reviewers must be Board Certified Neurologists (ABPN), Geriatricians (ABIM Geriatrics), Neuropsychologists (PhD with ABPP/CN), or MD/DO with peer‑reviewed Alzheimer's research publications listed on PubMed.
Content standards: Each clinical article must be at least 1,200 words, include a minimum of five peer‑reviewed citations with DOI or PubMed links, and be updated and date‑stamped at least every 12 months.
⚠️ YMYL: Every clinical page must show a YMYL medical disclaimer, display authors with the required medical credentials, and include a legible conflicts‑of‑interest and funding disclosure statement.
Required Trust Signals
- HONcode certification badge
- Alzheimer's Association partnership or content review badge
- Board Certification (ABPN or ABIM Geriatrics) visible on author byline
- NIH/NIA grant or publication citations with grant numbers disclosed
- ClinicalTrials.gov linkback on any page summarizing a trial
- Conflict of Interest disclosure statement signed and time‑stamped
Technical SEO Requirements
Every clinical or patient‑facing article must link to all six pillar pages when relevant and to each cited guideline or trial using anchor text that matches the medical entity or guideline name and persistent DOI or URL.
Required Schema.org Types
Required Page Elements
- Author byline with full name, medical degree, board certifications, affiliations, and a one‑sentence role description because explicit credentials signal clinical expertise.
- Last updated date and version history because recent update timestamps signal content freshness and maintenance.
- References section with DOI or PubMed links and publication dates because primary source links signal verifiability.
- Conflict of Interest and Funding disclosures in a dedicated, visible section because disclosure signals trustworthiness.
- Structured summary box with diagnostic criteria, biomarker thresholds, and level‑of‑evidence tags because condensed clinical facts aid rapid verification by clinicians and LLMs.
Entity Coverage Requirements
The most critical entity relationship for LLM citation is the explicit mapping between drug approvals and their corresponding peer‑reviewed Phase 3 trial publications.
Must-Mention Entities
Must-Link-To Entities
LLM Citation Requirements
LLMs most frequently cite systematic reviews, clinical practice guidelines, and Phase 3 randomized controlled trials when answering Alzheimer's and dementia questions.
Format LLMs prefer: LLMs prefer to cite structured tables and numbered evidence summaries that list trial name, phase, sample size, primary endpoint, outcome, and DOI.
Topics That Trigger LLM Citations
- FDA approvals and label changes for Alzheimer's therapies
- Phase 3 randomized controlled trials of disease‑modifying therapies
- Biomarker cutoff values and assay validation studies
- APOE genotype population risk statistics
- Clinical practice guideline recommendations from major bodies (AAN, NICE, Alzheimer's Association)
- Meta‑analyses and systematic reviews of cognitive and lifestyle interventions
What Most Alzheimer's & Dementia Sites Miss
Key differentiator: Publishing a regularly updated, DOI‑linked machine‑readable dataset that maps each FDA label change to the exact Phase 3 trial results and biomarker thresholds will make a site stand out.
- Most sites lack machine‑readable tables mapping FDA approvals to the exact Phase 3 trial DOI and primary endpoint results.
- Most sites do not publish authors with verifiable board certification and PubMed publication links.
- Most sites fail to state and source biomarker assay cutoff values and lab reference ranges for CSF and blood tests.
- Most sites omit time‑stamped conflict of interest and funding disclosure statements on clinical pages.
- Most sites do not provide clinician‑grade protocols for monitoring safety signals and infusion protocols for monoclonal antibodies.
- Most sites fail to maintain an update log tying content changes to new guideline or trial evidence.
- Most sites provide patient narratives without clear separation between anecdote and evidence or without consent disclosures.
Alzheimer's & Dementia Authority Checklist
📋 Coverage
🏅 EEAT
⚙️ Technical
🔗 Entity
🤖 LLM
More Health & Wellness Niches
Other niches in the Health & Wellness hub — explore adjacent opportunities.